Home » Stocks » ANAB

AnaptysBio, Inc. (ANAB)

Stock Price: $26.11 USD 0.48 (1.87%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
Market Cap 700.92M
Revenue (ttm) 18.00M
Net Income (ttm) -73.84M
Shares Out 27.32M
EPS (ttm) -2.71
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $26.11
Previous Close $25.63
Change ($) 0.48
Change (%) 1.87%
Day's Open 26.47
Day's Range 25.81 - 27.36
Day's Volume 461,683
52-Week Range 12.82 - 30.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 week ago

SAN DIEGO, Jan. 07, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging i...

Seeking Alpha - 1 month ago

AnaptysBio is a $675M clinical-stage biotechnology company focused on developing immunology therapeutics based around emerging immune control mechanisms applicable to inflammation and immuno-o...

GlobeNewsWire - 2 months ago

SAN DIEGO, Nov. 13, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging i...

GlobeNewsWire - 2 months ago

SAN DIEGO, Nov. 04, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging i...

Zacks Investment Research - 2 months ago

AnaptysBio (ANAB) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

Zacks Investment Research - 3 months ago

AnaptysBio (ANAB) reports positive top-line data from an interim analysis of its phase II GALLOP study on imsidolimab for the treatment of moderate-to-severe generalized pustular psoriasis.

GlobeNewsWire - 3 months ago

SAN DIEGO, Oct. 13, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging i...

GlobeNewsWire - 4 months ago

SAN DIEGO, Sept. 11, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet m...

Business Wire - 4 months ago

DENVER--(BUSINESS WIRE)--Shuman, Glenn & Stecker Investigates AnaptysBio, Inc.

Zacks Investment Research - 5 months ago

AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -5.33% and -100.00%, respectively, for the quarter ended June 2020.

GlobeNewsWire - 5 months ago

SAN DIEGO, Aug. 10, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging...

Zacks Investment Research - 5 months ago

AnaptysBio, Inc. (ANAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

GlobeNewsWire - 5 months ago

SAN DIEGO, Aug. 05, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet me...

GlobeNewsWire - 5 months ago

Dermatology Physician-Scientist To Lead Wholly-Owned Pipeline Advancement Dermatology Physician-Scientist To Lead Wholly-Owned Pipeline Advancement

GlobeNewsWire - 6 months ago

Appoints Dennis Mulroy as Chief Financial Officer and Eric Loumeau as Chief Operating Officer Appoints Dennis Mulroy as Chief Financial Officer and Eric Loumeau as Chief Operating Officer

GlobeNewsWire - 6 months ago

SAN DIEGO, July 08, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging...

Zacks Investment Research - 6 months ago

AnaptysBio, Inc. (ANAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

Zacks Investment Research - 7 months ago

Is (ANAB) Outperforming Other Medical Stocks This Year?

The Motley Fool - 7 months ago

The beaten-up biopharma provided an update that revved up interest in its pipeline.

PRNewsWire - 7 months ago

NEW YORK, May 19, 2020 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in AnaptysBio, Inc. ("Anaptys" or the "Company") (NASDAQ:ANAB) of the May...

PRNewsWire - 8 months ago

NEW YORK, May 15, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AnaptysBio, Inc. (NASDAQ: ANAB) between October 10, 2017 and N...

Zacks Investment Research - 8 months ago

As of late, it has definitely been a great time to be an investor AnaptysBio

Zacks Investment Research - 8 months ago

AnaptysBio (ANAB) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

The Motley Fool - 8 months ago

Key clinical trial results this quarter will determine the better buy.

Other stocks mentioned: EXEL
The Motley Fool - 9 months ago

This antibody drug developer can be had for fire-sale prices.

Zacks Investment Research - 9 months ago

AnaptysBio, Inc. (ANAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

The Motley Fool - 10 months ago

These three biopharma stocks all ended in positive territory Friday after a week of double-digit declines.

Other stocks mentioned: BLUE, EXEL
The Motley Fool - 10 months ago

Worries about a coronavirus impact don't make sense.

Other stocks mentioned: BLUE, EDIT
The Motley Fool - 10 months ago

A pair of black swans crushed these three healthcare stocks today.

Other stocks mentioned: CODX, NVAX
The Motley Fool - 10 months ago

After a rough 2019, investors are excited about the biotech's prospects in the year ahead.

Zacks Investment Research - 1 year ago

AnaptysBio, Inc. (ANAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

GuruFocus - 1 year ago

Falling knives are companies whose share prices have declined more than 59% over the past 12 months.

Other stocks mentioned: TC
Seeking Alpha - 1 year ago

AnaptysBio Is Due For A Bounce As It Trades Significantly Below Its Net Cash Per Share

Zacks Investment Research - 1 year ago

AnaptysBio has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

InvestorPlace - 1 year ago

AnaptysBio (ANAB) earnings for the antibody development company's third quarter of 2019 have ANAB stock taking a dive on Friday.

The Motley Fool - 1 year ago

A clinical trial flop doesn't leave the biotech a lot of options.

Benzinga - 1 year ago

AnaptysBio Inc (NASDAQ: ANAB) shares were taking a huge hit after the company announced a clinical pipeline update along with its third-quarter report.

Investors Business Daily - 1 year ago

AnaptysBio stock crashed Friday after the biotech said its experimental eczema treatment failed to pass muster in a Phase 2 study. Shares fell to their lowest-ever point in high volume.

Zacks Investment Research - 1 year ago

AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -2.68% and -100.00%, respectively, for the quarter ended September 2019.

GlobeNewsWire - 1 year ago

SAN DIEGO, Nov. 08, 2019 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet me...

Zacks Investment Research - 1 year ago

AnaptysBio, Inc. (ANAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Zacks Investment Research - 1 year ago

Top Ranked Momentum Stocks to Buy for October 31st

Other stocks mentioned: CUBI, DOOO
The Motley Fool - 1 year ago

Investors have lost faith in the biopharma, which is sitting at its lowest market cap in two years. But Wall Street may be overlooking a significant catalyst from a partnered asset.

Zacks Investment Research - 1 year ago

AnaptysBio (ANAB) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

The Motley Fool - 1 year ago

The company released some positive data yesterday...that wasn't positive enough.

Benzinga - 1 year ago

AnaptysBio Inc (NASDAQ: ANAB) released topline results Monday from an interim data analysis from a midstage study of its investigational asset ANAB019, which being evaluated for moderate-to-se...

Investors Business Daily - 1 year ago

AnaptysBio stock toppled Tuesday after the biotech company's psoriasis treatment failed to enthuse investors. The company tested just two patients vs.

GlobeNewsWire - 1 year ago

SAN DIEGO, Sept. 30, 2019 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet m...

GlobeNewsWire - 1 year ago

SAN DIEGO, Sept. 27, 2019 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet m...

The Motley Fool - 1 year ago

An executive's departure at a sensitive time has investors nervous.

About ANAB

AnaptysBio, a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. The company's products include Etokimab, an anti-interleukin (IL)-33 program for the treatment of atopic dermatitis, eosinophilic asthma, and chronic rhinosinusitis with nasal polyps; ANB019, an anti-IL-36 receptor for generalized pustular psoriasis and palmoplantar pustular psoriasis; and anti-inflammatory checkpoint modulators for inflammatory diseases. It is also developing immuno-oncology... [Read more...]

Industry
Biotechnology
IPO Date
Jan 26, 2017
CEO
Hamza Suria
Employees
89
Stock Exchange
NASDAQ
Ticker Symbol
ANAB
Full Company Profile

Financial Performance

In 2019, AnaptysBio's revenue was $8.00 million, an increase of 60.00% compared to the previous year's $5.00 million. Losses were -$97.34 million, 57.9% more than in 2018.

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for AnaptysBio stock is "Buy." The 12-month stock price forecast is 28.00, which is an increase of 7.24% from the latest price.

Price Target
$28.00
(7.24% upside)
Analyst Consensus: Buy